Kidney Disease: Three Studies At-a-Glance

Slideshow

Highlighted: Chronic kidney disease and stroke risk, syphilis in ESRD patients, and how healthy diets may reduce CKD incidence.

In this slideshow, we bring you several highlights from recent research in kidney disease. Scroll through the slides below to find out more about chronic kidney disease (CKD) and stroke risk, syphilis incidence in end-stage renal disease (ESRD) patients and implications for screening, and how healthy diets may reduce the global burden of CKD. 

Recent Videos
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
Tirzepatide Improves Heart Failure Symptoms and Renal Function in People with Obesity, CKD

Tirzepatide Improves Heart Failure Symptoms and Renal Function in People with Obesity, CKD

Sydney Jennings
April 11th 2025
Article

ACC 2025. Tirzepatide improved HF symptoms and renal function in patients with obesity-related HFpEF, regardless of CKD status, according to new findings from the SUMMIT trial.

Aprocitentan Reduces BP in Black Adults with Resistant Hypertension and Lowers Proteinuria / image courtesy of Tulane U School of Medicine

Aprocitentan Reduces BP in Black Adults with Resistant Hypertension and Lowers Proteinuria

Grace Halsey
April 9th 2025
Article

Aprocitentan, when added to background therapy of at least 3 antihypertensive agents, led to clinically meaningful and sustained BP reduction in this preplanned subanalysis.

Ozempic Approval Expanded to Include Patients with T2D and CKD: Daily Dose / image credit: ©New Africa/AdobeStock

Ozempic Approval Expanded to Include Patients with T2D and CKD: Daily Dose

Sydney Jennings
February 13th 2025
Article

Your daily dose of the clinical news you may have missed.

Lexicon Receives Complete Response Letter for Sotagliflozin in Type 1 Diabetes and Chronic Kidney Disease

Lexicon Receives Complete Response Letter for Sotagliflozin in Type 1 Diabetes and Chronic Kidney Disease

Denise Myshko
January 3rd 2025
Article

In November 2024, an FDA advisory committee said the benefits of sotagliflozin do not outweigh the risks in adults with type 1 diabetes and chronic kidney disease.

Data Published on Sotagliflozin Used to Reduce HbA1c in Adults with Type 1 Diabetes and Kidney Disease / image credit David Cherney UHN Research

Data Published on Sotagliflozin Used to Reduce HbA1c in Adults with Type 1 Diabetes and Kidney Disease

Grace Halsey
November 7th 2024
Article

The data, published in JASN, were presented last week to an FDA advisory committee considering recommending sotagliflozin as an adjunct to insulin in adults with T1D and CKD.

Sotagliflozin Setback: Cautionary FDA AdComm Vote Reflects Continued Concern for Negative Risk/Benefit Ratio in T1D with CKD / image credit ©Tada Images/stock.adobe.com

Sotagliflozin Setback: Cautionary FDA AdComm Vote Reflects Continued Concern for Negative Risk/Benefit Ratio in T1D with CKD

Grace Halsey
November 1st 2024
Article

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 11 to 3 against recommending the SGLT1/SLGT2 inhibitor to treat adults with T1D and CKD.

© 2025 MJH Life Sciences

All rights reserved.